Design Therapeutics Stock Total Debt
| DSGN Stock | USD 3.66 0.23 5.91% |
Design Therapeutics fundamentals help investors to digest information that contributes to Design Therapeutics' financial success or failures. It also enables traders to predict the movement of Design Stock. The fundamental analysis module provides a way to measure Design Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Design Therapeutics stock.
As of the 23rd of April 2024, Total Debt To Capitalization is likely to grow to 0.01. Design | Total Debt |
Design Therapeutics Company Total Debt Analysis
Design Therapeutics' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Design Therapeutics Total Debt | 2.33 M |
Most of Design Therapeutics' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Design Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Design Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Design Therapeutics is extremely important. It helps to project a fair market value of Design Stock properly, considering its historical fundamentals such as Total Debt. Since Design Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Design Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Design Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Design Total Debt Historical Pattern
Today, most investors in Design Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Design Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Design Therapeutics total debt as a starting point in their analysis.
Design Therapeutics Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Design Short Long Term Debt Total
Short Long Term Debt Total |
|
Based on the latest financial disclosure, Design Therapeutics has a Total Debt of 2.33 M. This is 99.92% lower than that of the Biotechnology sector and 99.28% lower than that of the Health Care industry. The total debt for all United States stocks is 99.96% higher than that of the company.
Design Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Design Therapeutics' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Design Therapeutics could also be used in its relative valuation, which is a method of valuing Design Therapeutics by comparing valuation metrics of similar companies.Design Therapeutics is currently under evaluation in total debt category among related companies.
Design Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Design Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Design Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Design Therapeutics' value.| Shares | Geode Capital Management, Llc | 2023-12-31 | 662.7 K | Renaissance Technologies Corp | 2023-12-31 | 648.8 K | Two Sigma Advisers, Llc | 2023-12-31 | 585 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 543.5 K | Two Sigma Investments Llc | 2023-12-31 | 428.2 K | Millennium Management Llc | 2023-12-31 | 420.1 K | Northern Trust Corp | 2023-12-31 | 372.9 K | Walleye Trading Advisors, Llc | 2023-12-31 | 362.4 K | Prescott Group Capital Management Llc | 2023-12-31 | 343 K | Sr One Capital Management, Lp | 2023-12-31 | 6.5 M | Logos Global Management Lp | 2023-12-31 | 5 M |
Design Fundamentals
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.15 | ||||
| Current Valuation | (58.99 M) | ||||
| Shares Outstanding | 56.49 M | ||||
| Shares Owned By Insiders | 36.66 % | ||||
| Shares Owned By Institutions | 56.82 % | ||||
| Number Of Shares Shorted | 2.23 M | ||||
| Price To Book | 0.75 X | ||||
| Price To Sales | 22,642 X | ||||
| Gross Profit | (48.61 M) | ||||
| EBITDA | (78.19 M) | ||||
| Net Income | (66.86 M) | ||||
| Cash And Equivalents | 359.38 M | ||||
| Cash Per Share | 6.45 X | ||||
| Total Debt | 2.33 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 48.96 X | ||||
| Book Value Per Share | 4.92 X | ||||
| Cash Flow From Operations | (58.56 M) | ||||
| Short Ratio | 7.35 X | ||||
| Earnings Per Share | (1.19) X | ||||
| Target Price | 4.75 | ||||
| Number Of Employees | 58 | ||||
| Beta | 1.83 | ||||
| Market Capitalization | 219.76 M | ||||
| Total Asset | 289.64 M | ||||
| Retained Earnings | (177.63 M) | ||||
| Working Capital | 274.96 M | ||||
| Net Asset | 289.64 M |
About Design Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Design Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Design Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Design Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Design Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Design Therapeutics' short interest history, or implied volatility extrapolated from Design Therapeutics options trading.
Pair Trading with Design Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Design Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Design Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Design Stock
| 0.7 | PCRX | Pacira Pharmaceuticals Earnings Call Next Week | PairCorr |
| 0.66 | MGTX | MeiraGTx Holdings PLC Financial Report 9th of May 2024 | PairCorr |
| 0.63 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
| 0.59 | ANAB | AnaptysBio Financial Report 9th of May 2024 | PairCorr |
| 0.55 | ALKS | Alkermes Plc Earnings Call Next Week | PairCorr |
The ability to find closely correlated positions to Design Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Design Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Design Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Design Therapeutics to buy it.
The correlation of Design Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Design Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Design Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Design Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Design Therapeutics Piotroski F Score and Design Therapeutics Altman Z Score analysis. To learn how to invest in Design Stock, please use our How to Invest in Design Therapeutics guide.Note that the Design Therapeutics information on this page should be used as a complementary analysis to other Design Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Complementary Tools for Design Stock analysis
When running Design Therapeutics' price analysis, check to measure Design Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Design Therapeutics is operating at the current time. Most of Design Therapeutics' value examination focuses on studying past and present price action to predict the probability of Design Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Design Therapeutics' price. Additionally, you may evaluate how the addition of Design Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities |
Is Design Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Design Therapeutics. If investors know Design will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Design Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.19) | Revenue Per Share 0.001 | Return On Assets (0.15) | Return On Equity (0.22) |
The market value of Design Therapeutics is measured differently than its book value, which is the value of Design that is recorded on the company's balance sheet. Investors also form their own opinion of Design Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Design Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Design Therapeutics' market value can be influenced by many factors that don't directly affect Design Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Design Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Design Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Design Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.